Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 1/20 | 0.36 |
| ▸ | PNMT | P11086 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.30 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.30 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.30 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21296443 | 0.78 | MEN1 (0.41) | GRIA2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL29425269 | 0.78 | MEN1 (0.41) | GRIA2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL10352631 | 0.77 | ALDH1A1 (0.46) | — | |
| SCHEMBL14249547 | 0.73 | ALDH1A1 (0.40) | GRIA2 | |
| SCHEMBL29278536 | 0.70 | GRIA2 (0.37) | GRIA2 | |
| Succinimide SCHEMBL28711840 | 0.65 | DTYMK (0.43) | GRIA2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL16002308 | 0.64 | PDK1 (0.44) | GRIA2 | |
| SCHEMBL20395675 | 0.63 | MEN1 (0.54) | GRIA2 | |
| SCHEMBL28234745 | 0.63 | GRIA2 (0.44) | GRIA2 | |
| SCHEMBL11232423 | 0.63 | ALDH1A1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240091315-A1 | XTEN CONJUGATE COMPOSITIONS AND METHODS OF MAKING SAME | AMUNIX PHARMACEUTICALS, INC. | 2024-03-21 | — | — | US | disclosed |
| US-20210322518-A1 | XTEN CONJUGATE COMPOSITIONS AND METHODS OF MAKING SAME | AMUNIX PHARMACEUTICALS, INC. | 2021-10-21 | — | — | US | disclosed |
| US-10953073-B2 | XTEN conjugate compositions and methods of making same | AMUNIX PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| WO-2020264132-A1 | WOUND INSERTS FOR TREATMENT OF TUNNELING WOUNDS | KCI LICENSING, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| US-20190083577-A1 | XTEN CONJUGATE COMPOSITIONS AND METHODS OF MAKING SAME | AMUNIX PHARMACEUTICALS, INC. | 2019-03-21 | — | — | US | disclosed |
| US-10172953-B2 | XTEN conjugate compositions and methods of making same | AMUNIX OPERATING INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20150037359-A1 | XTEN CONJUGATE COMPOSITIONS AND METHODS OF MAKING SAME | Amunix Operating, Inc. (US) | 2015-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150037359-A1 | XTEN CONJUGATE COMPOSITIONS AND METHODS OF MAKING SAME | XPA, TXLNA, NGLY1 | GRIA2 3354/4885PNMT 3651/4885GABRA1 3351/4885 |
| US-10172953-B2 | XTEN conjugate compositions and methods of making same | XPA, TXLNA, NGLY1 | GRIA2 3354/4885PNMT 3651/4885GABRA1 3351/4885 |
| US-20210322518-A1 | XTEN CONJUGATE COMPOSITIONS AND METHODS OF MAKING SAME | XPA, TXLNA, NGLY1 | GRIA2 3354/4885PNMT 3651/4885GABRA1 3351/4885 |
| US-10953073-B2 | XTEN conjugate compositions and methods of making same | XPA, TXLNA, NGLY1 | GRIA2 3354/4885PNMT 3651/4885GABRA1 3351/4885 |
| US-20190083577-A1 | XTEN CONJUGATE COMPOSITIONS AND METHODS OF MAKING SAME | XPA, TXLNA, NGLY1 | GRIA2 3354/4885PNMT 3651/4885GABRA1 3351/4885 |
| US-20240091315-A1 | XTEN CONJUGATE COMPOSITIONS AND METHODS OF MAKING SAME | XPA, TXLNA, NGLY1 | GRIA2 3354/4885PNMT 3651/4885GABRA1 3351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.